Vedolizumab is a medicine that helps reduce inflammation and pain in the digestive system. This study is for kids and teens with moderate to severe Crohn's disease (CD), a condition that causes inflammation in the digestive tract. The goal is to see if taking vedolizumab helps the symptoms get better or go away, which is called remission. Participants will get 3 infusions over 6 weeks. If they respond, they will continue with either a high or low dose every 8 weeks. The study lasts until Week 54, and if symptoms don’t improve, participants might need more medicine.

• The study lasts over a year, with visits every 8 weeks after the initial 6 weeks.
• Participants may continue in an extension study if they do well.
• There are certain criteria to join, like age and previous treatments.